Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the firm's stock in a transaction on Monday, November 24th. The stock was sold at an average price of $90.36, for a total value of $451,800.00. Following the completion of the transaction, the chief executive officer owned 2,307,500 shares in the company, valued at $208,505,700. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

iRadimed Stock Up 0.9%

NASDAQ IRMD traded up $0.79 on Monday, reaching $90.31. The company had a trading volume of 104,269 shares, compared to its average volume of 49,817. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $91.06. The stock's 50 day moving average is $77.19 and its 200-day moving average is $67.36. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 55.75 and a beta of 1.04.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.50 million. iRadimed had a return on equity of 23.30% and a net margin of 26.61%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS. FY 2025 guidance at 1.840-1.880 EPS. As a group, analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 25th. Investors of record on Friday, November 14th will be issued a dividend of $0.17 per share. The ex-dividend date is Friday, November 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.8%. iRadimed's payout ratio is currently 41.21%.

Institutional Investors Weigh In On iRadimed

Several institutional investors have recently bought and sold shares of IRMD. Roubaix Capital LLC bought a new position in shares of iRadimed during the 1st quarter worth approximately $2,526,000. SG Americas Securities LLC boosted its holdings in iRadimed by 408.8% during the second quarter. SG Americas Securities LLC now owns 36,516 shares of the medical equipment provider's stock worth $2,183,000 after purchasing an additional 29,339 shares during the last quarter. Nuveen LLC acquired a new position in iRadimed during the first quarter worth $1,418,000. Johnson Investment Counsel Inc. bought a new position in iRadimed in the second quarter valued at $1,534,000. Finally, Algert Global LLC increased its stake in iRadimed by 87.5% in the 3rd quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider's stock valued at $3,615,000 after buying an additional 23,710 shares during the last quarter. Institutional investors own 92.34% of the company's stock.

Analyst Ratings Changes

IRMD has been the topic of several analyst reports. Wall Street Zen lowered shares of iRadimed from a "strong-buy" rating to a "buy" rating in a report on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a "hold" rating in a research report on Tuesday, November 4th. Roth Capital set a $90.00 target price on iRadimed in a report on Friday, October 31st. Weiss Ratings reissued a "buy (b)" rating on shares of iRadimed in a research note on Friday, October 31st. Finally, Lake Street Capital restated a "buy" rating and issued a $100.00 price target on shares of iRadimed in a report on Monday, November 3rd. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.33.

View Our Latest Research Report on iRadimed

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Featured Articles

• Five stocks we like better than iRadimed
• How to Invest in the Best Canadian Stocks
• Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Retail Stocks Investing, Explained
• Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
• Why Are These Companies Considered Blue Chips?
• JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iRadimed Right Now?

Before you consider iRadimed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.

While iRadimed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here